no treatment versus 24 or 60 weeks of antiretroviral treatment during primary hiv infection the randomized primo-shm trial没有治疗与24或60周的抗逆转录病毒治疗期间主要hiv感染随机primo-shm试验.pdfVIP

No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial 1. 1,2. 2 3 Marlous L. Grijsen *, Radjin Steingrover , Ferdinand W. N. M. Wit , Suzanne Jurriaans , 4¤ 5 6 7 8 Annelies Verbon , Kees Brinkman , Marchina E. van der Ende , Robin Soetekouw , Frank de Wolf , 2 9 1 Joep M. A. Lange , Hanneke Schuitemaker , Jan M. Prins , on behalf of the Primo-SHM Study Group 1 Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2 Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 3 Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 4 Department of Medical Microbiology, Maastricht University Medical Center, Maastricht, The Netherlands, 5 Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands, 6 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, 7 Department of Internal Medicine, Kennemer Gasthuis, Haarlem, The Netherlands, 8 HIV Monitoring Foundation, Amsterdam, The Netherlands, 9 Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Abstract Background: The objective of this study was to assess the benefit of temporary combin